Birdwatch Note
2024-10-18 03:59:15 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
イギリス保険証はコロナウイルスなんかなかったといっているという動画前半の主張に関して 勿論、そんな訳はなく、英国では現在もコロナワクチンが新型コロナウイルス感染症のために推奨されています。 https://ukhsa.blog.gov.uk/2024/08/02/whos-eligible-for-the-2024-covid-19-vaccine-or-autumn-booster/ イベルメクチンという奇跡の薬が認可されず、なぜかワクチンばかりという動画後半の主張について 興和、北里のイベルメクチンの2つのランダム化比較試験(RCT)で新型コロナへの有効性は見だされず https://www.kowa.co.jp/news/2022/press20220926.html https://www.kitasato-u.ac.jp/khp/topics/2022/20220930.html 世界的にもRCTのメタ解析でも臨床アウトカムの改善への有効性は見だされていません。 https://academic.oup.com/cid/article/74/6/1022/6310839?login=false https://www.sciencedirect.com/science/article/pii/S0924857924001663?casa_token=BShl-qSiS2EAAAAA:lUaSQL960ThyZdOKwn5PXDJTZs6a3fQy_rFZ-vBBLIBKnjXOjZ-4Tve4AD5lkpkz5BslvBge0z8 臨床試験で有効性が見だせなかった薬は一般に承認されない事に注意が必要です。
Written by F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1847090318875021490
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1847125264335307098
- noteId - 1847125264335307098
- participantId -
- noteAuthorParticipantId - F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D Participant Details
- createdAtMillis - 1729223955603
- tweetId - 1847090318875021490
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 1
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- イギリス保険証はコロナウイルスなんかなかったといっているという動画前半の主張に関して 勿論、そんな訳はなく、英国では現在もコロナワクチンが新型コロナウイルス感染症のために推奨されています。 https://ukhsa.blog.gov.uk/2024/08/02/whos-eligible-for-the-2024-covid-19-vaccine-or-autumn-booster/ イベルメクチンという奇跡の薬が認可されず、なぜかワクチンばかりという動画後半の主張について 興和、北里のイベルメクチンの2つのランダム化比較試験(RCT)で新型コロナへの有効性は見だされず https://www.kowa.co.jp/news/2022/press20220926.html https://www.kitasato-u.ac.jp/khp/topics/2022/20220930.html 世界的にもRCTのメタ解析でも臨床アウトカムの改善への有効性は見だされていません。 https://academic.oup.com/cid/article/74/6/1022/6310839?login=false https://www.sciencedirect.com/science/article/pii/S0924857924001663?casa_token=BShl-qSiS2EAAAAA:lUaSQL960ThyZdOKwn5PXDJTZs6a3fQy_rFZ-vBBLIBKnjXOjZ-4Tve4AD5lkpkz5BslvBge0z8 臨床試験で有効性が見だせなかった薬は一般に承認されない事に注意が必要です。
Note Ratings
rated at | rated by | |
2024-10-18 12:41:15 -0500 | Rating Details | |
2024-10-18 10:18:35 -0500 | Rating Details | |
2024-10-18 10:07:39 -0500 | Rating Details | |
2024-10-18 06:47:53 -0500 | Rating Details | |
2024-10-18 06:14:57 -0500 | Rating Details | |
2024-10-18 06:09:19 -0500 | Rating Details | |
2024-10-18 04:44:00 -0500 | Rating Details | |
2024-10-18 03:17:58 -0500 | Rating Details | |
2024-10-18 01:42:34 -0500 | Rating Details | |
2024-10-18 01:33:57 -0500 | Rating Details | |
2024-10-18 00:39:13 -0500 | Rating Details | |
2024-10-17 23:33:19 -0500 | Rating Details | |
2024-10-17 23:32:20 -0500 | Rating Details | |
2024-10-17 23:30:27 -0500 | Rating Details | |
2024-10-17 23:26:23 -0500 | Rating Details | |
2024-10-17 23:25:58 -0500 | Rating Details | |
2024-10-17 23:16:24 -0500 | Rating Details | |
2024-10-18 07:10:45 -0500 | Rating Details | |
2024-10-18 07:08:26 -0500 | Rating Details | |
2024-10-18 06:33:12 -0500 | Rating Details | |
2024-10-18 06:27:51 -0500 | Rating Details | |
2024-10-18 05:40:49 -0500 | Rating Details | |
2024-10-18 05:08:12 -0500 | Rating Details | |
2024-10-18 04:39:28 -0500 | Rating Details | |
2024-10-18 03:43:17 -0500 | Rating Details | |
2024-10-18 03:23:29 -0500 | Rating Details | |
2024-10-18 02:38:39 -0500 | Rating Details | |
2024-10-18 01:32:00 -0500 | Rating Details | |
2024-10-18 00:43:11 -0500 | Rating Details | |
2024-10-18 00:29:40 -0500 | Rating Details | |
2024-10-18 00:12:18 -0500 | Rating Details | |
2024-10-17 23:58:01 -0500 | Rating Details | |
2024-10-17 23:37:06 -0500 | Rating Details | |
2024-10-17 23:26:53 -0500 | Rating Details | |
2024-10-17 23:10:02 -0500 | Rating Details | |
2024-10-19 18:08:59 -0500 | Rating Details | |
2024-10-19 12:57:53 -0500 | Rating Details | |
2024-10-19 09:32:06 -0500 | Rating Details | |
2024-10-19 06:15:51 -0500 | Rating Details | |
2024-10-19 04:20:04 -0500 | Rating Details | |
2024-10-18 10:19:22 -0500 | Rating Details | |
2024-10-18 08:57:28 -0500 | Rating Details | |
2024-10-18 08:26:03 -0500 | Rating Details | |
2024-10-18 04:35:04 -0500 | Rating Details | |
2024-10-18 03:32:41 -0500 | Rating Details | |
2024-10-18 03:04:41 -0500 | Rating Details | |
2024-10-18 02:48:04 -0500 | Rating Details | |
2024-10-18 02:32:34 -0500 | Rating Details | |
2024-10-18 02:31:45 -0500 | Rating Details | |
2024-10-18 02:09:38 -0500 | Rating Details | |
2024-10-18 01:06:04 -0500 | Rating Details | |
2024-10-18 00:19:36 -0500 | Rating Details | |
2024-10-18 00:15:56 -0500 | Rating Details | |
2024-10-18 00:10:32 -0500 | Rating Details | |
2024-10-17 23:22:50 -0500 | Rating Details | |
2024-10-17 23:21:23 -0500 | Rating Details | |
2024-10-17 23:20:18 -0500 | Rating Details | |
2024-10-17 23:17:18 -0500 | Rating Details | |
2024-10-17 23:10:18 -0500 | Rating Details | |
2024-10-17 23:10:16 -0500 | Rating Details | |
2024-10-18 05:24:08 -0500 | Rating Details | |
2024-10-18 05:23:28 -0500 | Rating Details | |
2024-10-18 04:40:56 -0500 | Rating Details | |
2024-10-18 03:06:32 -0500 | Rating Details | |
2024-10-18 02:55:50 -0500 | Rating Details | |
2024-10-18 02:19:49 -0500 | Rating Details | |
2024-10-18 02:14:57 -0500 | Rating Details | |
2024-10-18 01:09:15 -0500 | Rating Details | |
2024-10-18 01:06:03 -0500 | Rating Details | |
2024-10-18 00:42:26 -0500 | Rating Details | |
2024-10-18 00:06:04 -0500 | Rating Details | |
2024-10-18 00:02:22 -0500 | Rating Details | |
2024-10-18 00:01:07 -0500 | Rating Details | |
2024-10-17 23:45:52 -0500 | Rating Details | |
2024-10-17 23:43:44 -0500 | Rating Details | |
2024-10-17 23:35:09 -0500 | Rating Details | |
2024-10-17 23:19:09 -0500 | Rating Details | |
2024-10-18 23:57:13 -0500 | Rating Details | |
2024-10-18 20:19:43 -0500 | Rating Details | |
2024-10-18 15:00:11 -0500 | Rating Details | |
2024-10-18 07:29:57 -0500 | Rating Details | |
2024-10-18 06:09:36 -0500 | Rating Details | |
2024-10-18 04:11:04 -0500 | Rating Details | |
2024-10-18 04:06:33 -0500 | Rating Details | |
2024-10-18 03:42:03 -0500 | Rating Details | |
2024-10-18 03:23:50 -0500 | Rating Details | |
2024-10-18 03:01:42 -0500 | Rating Details | |
2024-10-18 02:35:47 -0500 | Rating Details | |
2024-10-18 02:24:49 -0500 | Rating Details | |
2024-10-18 01:22:18 -0500 | Rating Details | |
2024-10-18 00:53:45 -0500 | Rating Details | |
2024-10-18 00:53:07 -0500 | Rating Details | |
2024-10-17 23:56:53 -0500 | Rating Details | |
2024-10-17 23:40:30 -0500 | Rating Details | |
2024-10-17 23:40:24 -0500 | Rating Details | |
2024-10-17 23:27:50 -0500 | Rating Details | |
2024-10-17 23:13:16 -0500 | Rating Details |